For Immediate Release

June 6, 2005

Contact: CAUSE Marketing, LLC

Media Contact: Corin Walson

Office: 714/ 921.6925

Mobile: 714/ 865.4147

Email: cwalson@4causemarketing.com

National Fibromyalgia Association and Swiss Medica launch 024™ pain reliever at National Association of Chain Drug Stores (NACDS) Marketplace 2005 Conference

NEW ORLEANS,---. – June 6, 2005 – Swiss Medica Inc. (OTC BB: SWME) announced the launch of its keenly anticipated O24™ Fibromyalgia pain reliever during a joint press announcement with the National Fibromyalgia Association at the National Association of Chain Drug Stores Marketplace conference in New Orleans.

Available at 13,000 pharmacy outlets this summer, the 024™ pain reliever is the first product of its kind developed to specifically address the symptoms of long term pain associated with fibromyalgia syndrome and is a patented and clinically tested, strong and safe, all-natural, over-the-counter health product. It is also the first product of its kind carrying the NFA’s official Seal of Approval. As part of the alliance with Swiss Medica, the NFA will receive a percentage of the proceeds from sales of 024™.

"Working with the National Fibromyalgia Association will provide Swiss Medica with a unique opportunity to introduce our patented, safe, effective and completely natural pain relief technology to people with fibromyalgia,” said Grant Johnson, President of Swiss Medica Inc. “It’s also the start of an on-going commitment to support the much-needed services that the NFA provides to fibromyalgia sufferers."

Fibromyalgia, a common and chronic disorder characterized by widespread muscle pain, fatigue, and multiple tender points , affects between 6 million and 10 million Americans, according to expert estimates. The National Fibromyalgia Association estimates that 3% to 6% of the U.S. population has fibromyalgia.

Said Lynne Matallana, president and founder of the National Fibromyalgia Association, “We are very pleased that Swiss Medica has developed a product that has been clinically shown to be effective for fibromyalgia pain, and is also committed to helping support patient service programs and future research implemented by the NFA to directly benefit the fibromyalgia community.”

Study results

The launching of 024™ included unveiling the results of a randomized double blind clinical trial which compared the O24™ pain reliever against a placebo on patients suffering from fibromyalgia. In the pilot study of 153 fibromyalgia subjects conducted over a 4-6 week period, 133 participants (87%) completed the study with 68 (51%) using a placebo. The other 65 (49%) used the O24™ product. Assessments of these participants were carried out at multiple community clinics in the Greater Toronto Area. The group treated with O24™ showed statistically significant improvement when measured on the Visual Analog Scale for pain, according to reports.

About Swiss Medica Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. The company increases its market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com and www.O24zone.com and www.pmsescape.com

About the National Fibromyalgia Association

The National Fibromyalgia Association (NFA) is a nonprofit [501 (c (3)] organization whose mission is to develop and execute programs dedicated to improving the quality of life for people with fibromyalgia. The NFA produces educational materials, sponsors CME and patient conferences, hosts a web site (www.FMaware.org), and publishes Fibromyalgia AWARE, the first and only consumer magazine for people with fibromyalgia, chronic pain and other invisible illnesses.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

---#---